



ANDA 206788

**ANDA APPROVAL**

Hetero USA, Inc.  
U.S. Agent for Hetero Labs Limited Unit V  
1035 Centennial Avenue  
Piscataway, NJ 08854  
Attention: Soma Raju Indukuri  
Vice President, Regulatory Affairs

Dear Soma Raju Indukuri:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on January 7, 2014, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg.

Reference is also made to the tentative approval letter issued by this office on July 6, 2016, the complete response letter issued by this office on October 30, 2024, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg, of Novartis Pharmaceuticals Corporation (Novartis), NDA - 022291.

The RLD upon which you have based your ANDA, Novartis's Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg, is subject to periods of patent protection. The following patents and expiration dates (with pediatric exclusivity added) are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
7,547,719 (the '719 patent)	January 13, 2026
8,052,993 (the '993 patent)	February 1, 2028
8,052,994 (the '994 patent)	February 1, 2028

8,062,665 (the '665 patent) February 1, 2028

8,071,129 (the '129 patent) February 1, 2028

8,828,430 (the '430 patent) February 1, 2028

With respect to the '719 patent pertaining to the use code (b) (4)

(b) (4), your ANDA contains a statement under section 505(j)(2)(A)(viii) of the FD&C Act that this is a method-of-use patent that does not claim any indication for which you are seeking approval under your ANDA.

With respect to 1) '993, '994, '665, '129, and '430 patents and 2) the '719 (excluding those portions pertaining to (b) (4)

(b) (4)

(b) (4)<sup>1</sup> your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg, under this ANDA. You have notified the Agency that Hetero Labs Limited Unit V (Hetero) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that no action for infringement was brought against Hetero within the statutory 45-day period.

With respect to 180-day generic drug exclusivity, we note that Hetero was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg. Therefore, with this approval, Hetero is eligible for 180 days of generic drug exclusivity for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg. FDA notes that after issuance of this approval letter, eligibility for 180-day exclusivity is subject to future events that may result in forfeiture of exclusivity under section 505(j)(5)(D) of the FD&C Act. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, begins to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA notifying the Agency within 30 days of the date of the first commercial marketing of this drug product or the RLD. If you do not notify the Agency within 30 days, the date of first commercial marketing will be deemed to be the date of the drug product's approval. See 21 CFR 314.107(c)(2).

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

### **COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly

stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

## **REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL**

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

*{See appended electronic signature page}*

For Edward M. Sherwood  
Director  
Office of Regulatory Operations  
Office of Generic Drugs  
Center for Drug Evaluation and Research

---

<sup>1</sup> The Agency notes that the '993 (for the 12.5 mg, 50 mg, and 75 mg strengths only), '994 (for the 12.5 mg, 25 mg, and 75 mg strengths only), '665 (for the 12.5 mg, 25 mg, and 50 mg strengths only), '129 (for the 25 mg, 50 mg, and 75 mg strengths only), and '430 patents were submitted to the agency after submission of your ANDA. Litigation, if any, with respect to these patents would not create a statutory stay of approval.



Julie  
Kuriakose

Digitally signed by Julie Kuriakose

Date: 1/17/2025 02:24:00PM

GUID: 556dc322004ee2eb183a54842fb7fae3